Study Of The Cardiotoxicity Protection And The Influence Therapeutic Effect Of Dexrazoxane On Epirubicin

Objective(s):To verify epirubicin (EPI) combine with cardioprotective agent dexrazoxane (DZR) does not affect the efficacy of epirubicin treatment of breast cancer, and dexrazoxane can reduce epirubicin-induced cardiotoxicity.Methods:Construct the 4T1-luc cells:use pBabe retrovirus system luc (luciferase gene) into the infected 4T1 (murine breast cancer) cells. Establish mice model of breast cancer:be prepared to adjust the number of 4T1-luc cells to 1×106/ml, were inoculated subcutaneously abdominal 4th breast of Balb/c mice with 0.1ml. When the tumor grew to about 5mm* 5mm, randomly divided into three groups of 18. Blank control group:equal volumes saline.Experimental group:epirubicin (8mg/kg) combine dexrazoxane (120mg/kg). Control group:alone epirubicin (8mg/kg). They are used enterocoelia injectionon(EI), administered once every 7 days as one cycle.ln terms of efficacy evaluation:every 2 days once measure the tumor volume size, every 7 days observe the growth and metastasis of tumor in vivo situation by fluorescence imaging.2 cycles per each group were sacrificed 6 mice breast cancer, weighed the tumor tissue. In cardiac toxicity assessment:administration every 2 cycles in each group were sacrificed 6 mice were isolated cardiac tissue biopsy done after fixation, after HE staining pathological changes in myocardial tissue.Results:1.efficacy aspects:Tumor volume measurements:the control group and the experimental group showed significant inhibition of blank group and the experimental group compared to the control group also showed better efficacy. Weighing tumor:tumor weight in the control group and the experimental group were lighter than the blank group, but the control group and the experimental group tumor weight contrast no significant difference. Fluorescence measurement:fluorescence photons blank group was significantly higher than the experimental group and the control group, but no statistical difference comparing control and experimental groups. 2.cardiac toxicity:Experimental group showed myocardial hyaline myocardial interstitial bleeding, eosinophils increased, wavy patterns and changes in the control group showed myocardial interstitial bleeding, eosinophils increased, vacuolar degeneration, wavy pattern changes, inflammatory cell infiltration, myocardial rupture, cell coagulation necrosis and other changes. Myocardial injury control group and the experimental group increased with dose increases. Overall damage is myocardial injury in the experimental group than the control group light.Conclusions:Epirubicin (EPI) combine with dexrazoxane (DZR) does not affect the efficacy of epirubicin treatment of breast cancer, and dexrazoxane can reduce epirubicin-induced cardiotoxicity.